Literature DB >> 11175341

Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.

S J Lim1, G Lopez-Berestein, M C Hung, R Lupu, A M Tari.   

Abstract

ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These findings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the effects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin. Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-overexpressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11175341     DOI: 10.1038/sj.onc.1204014

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer.

Authors:  Guoxin Zhang; Bin He; Georg F Weber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

2.  MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia.

Authors:  Sugunavathi Sepramaniam; Arunmozhiarasi Armugam; Kai Ying Lim; Dwi Setyowati Karolina; Priyadharshni Swaminathan; Jun Rong Tan; Kandiah Jeyaseelan
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

3.  Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.

Authors:  Brunilde Gril; Michel Vidal; Franck Assayag; Marie-France Poupon; Wang-Qing Liu; Christiane Garbay
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

4.  PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2.

Authors:  Danielle K Lynch; Roger J Daly
Journal:  EMBO J       Date:  2002-01-15       Impact factor: 11.598

5.  KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2.

Authors:  Xiao-Ping Zang; Doris R Siwak; Thi X Nguyen; Ana M Tari; J Thomas Pento
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Binding of the cSH3 domain of Grb2 adaptor to two distinct RXXK motifs within Gab1 docker employs differential mechanisms.

Authors:  Caleb B McDonald; Kenneth L Seldeen; Brian J Deegan; Vikas Bhat; Amjad Farooq
Journal:  J Mol Recognit       Date:  2010-12-13       Impact factor: 2.137

7.  Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.

Authors:  Sheng Jiang; Chenzhong Liao; Lakshman Bindu; Biaolin Yin; Karen W Worthy; Robert J Fisher; Terrence R Burke; Marc C Nicklaus; Peter P Roller
Journal:  Bioorg Med Chem Lett       Date:  2009-03-29       Impact factor: 2.823

8.  Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.

Authors:  Yeon Hee Park; Hyun-Tae Shin; Hae Hyun Jung; Yoon-La Choi; TaeJin Ahn; Kyunghee Park; Aeri Lee; In-Gu Do; Ji-Yeon Kim; Jin Seok Ahn; Woong-Yang Park; Young-Hyuck Im
Journal:  Oncotarget       Date:  2015-10-13

9.  KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma.

Authors:  Xiuzhi Zhang; Jialing Zhang; Fenglan Gao; Shasha Fan; Liping Dai; Jinzhong Zhang
Journal:  Front Genet       Date:  2020-10-26       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.